Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Revolutionary Autoinjector Pushes the Limits of High Viscosity Drug Delivery

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Oval Medical Technologies Ltd announced that a variety of 1100 cPs solutions have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector.

Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector technology solves currently unsolvable problems in the industry for drug containment and for the end user. Oval are highly focussed and agile, and it is therefore not surprising that they are proving to be a global success and are continuously growing their team.

The automatic delivery of high viscosity drugs is an important milestone for injection delivery, as there is currently no-known automatic injection device, with a needle, on the market which can deliver these viscosities. Viscosity has been a huge problem for many biopharmaceutical formulators as many biologics are very viscous. There has been no effective way of delivering high viscosity drugs through a prefilled syringe, without extreme pain to the patient (due a large needle bore) and physical discomfort, to the care-giver, when administering the injection (due to high injection forces). Not only does this mean that these wonder drugs (often coined magic bullets) can be administered through the Oval device, but they can be administered by the patient in the comfort of their own home.

Oval has wide experimental expertise in the design and testing of primary drug containers, for high viscosity drugs, in their specifically designed laboratories. Testing of pharmaceutical companies’ drugs, to see if they can be delivered in an Oval device, is proving to be a popular service for biopharmaceutical companies. Oval also has a new technology which should enable much higher viscosities (100,000 cPs) to be administered subcutaneously.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!